Lupin gets US FDA approval for anti-diabetes drug

PrandiMet has been approved to lower blood glucose in adult patients

Lupin Limited received an approval from the US Food and Drug Administration (U SFDA) for generic PrandiMet, also known as Prandin used in type 2 diabetes.

Danish pharma company Novo Nordisk is the innovator of the drug that has been approved to lower blood glucose in adult patients.

The product is expected to have sales of $200-$300 million in the US. The drug could be limited competition for the company and can contribute around $ 50 million on sales, according to Sarabjit Kour Nangra of Angel Broking.